Added at 24, 6 or just prior to HSV-2 inoculation (104pfu/well)
Result:
The 6 μg does produced significant reductions when delivered at 24 or 6 h prior to HSV-2 inoculation. The 0.1 μg dose produced reduced HSV-2 replication at 24 or 6 h prior to viral challenge.
动物实验
Animal Model [1]:
Female Swiss-Webster mice (weighing 20-25 g)
Dosage:
2 or 6 μg
Administration:
Delivered vaginally using a positive displacement pipet, prior to or following viral challenge as specified for each experiment.
Result:
The 2 μg does delivered 6 h prior to HSV-2 challenge increased the ID50 (260 pfu) and LD50 (660 pfu) by 10-fold compared to DPBS vehicle control.
The single 6 μg dose produced significantly improved outcomes compared to DPBS vehicle application.